[MIK HOT SPOT_KHIDI] Arcaeir develops Organ On-Chip that helps prescribe customized drugs for cardiovascular patients
[ Jane Lee 2020-06-22 ]  
Email
Print

AVING News interviewed Shin Gyeong-cheol, the CEO of Arcaeir, which participated in the MIK HOT SPOT (Made in Korea Online Exhibition) KHIDI.

Please introduce your company briefly.

The company was founded on June 29, 2013. We separate and refine carotenoids mainly from marine microorganisms, and develop the product to make drugs and health foods. Also, to screen the drugs, we have developed a system called organ-on-chip, developing the equipment to screen the drug's efficacy and toxicity.

Overview of major system

What we do is separating and refining lansis beta-carotene with different isomers in carotenoids from marine microorganisms for mass production. We have surpassed the technology that goes beyond refining from natural products, and can now synthesize them.


Our synthesis technology boasts remarkable synthetic yields. Currently, it has a purity of 99.9%, which is almost 100%. It is being developed for making cardiovascular treatment drugs.

Currently, we have finished clinical trials, and we aim to enter the commercial market within one to two years. And, we use a rather different and difficult method for drug screening, which is to use real human blood to stick the organ cells into the chip. By using blood circulation, various efficacy or toxicity from it can be checked. This is the system we are developing. The system is already in the second version. In the third version, the blood cell measuring system will probably be included in the system.

Future plans

Providing personalized drug service screening to those who are developing new drugs or those with serious illnesses is our short-term goal. In the long run, there are a lot of rare and cardiovascular diseases opportunities because we are working on the cardiovascular system. Especially for Marfan syndrome or something like this, you have to be careful, or the heart may rupture. We are going to do research in conjunction with genetic factors.

Now, we are developing version 2 with the development of organ-on-chip already completed. We are now working on receiving approval on the medical device. Until 2023, we are going to develop the system that has the automatic blood cell measuring instrument attached to the organ-on-chip and see the results. We are aiming at completing this by 2023. For version 3, what we are going to do is to joint research with a company in Czech Republic.

Corporate value that we pursue

The corporate value we are striving for is to focus on the chronic diseases or senile diseases. Above all, it is still not clearly defined as to how such diseases started, and what procedure should be taken to treat them. So basically, we first defined the cause of the illnesses, and tried to find the ways to treat them. In the future, depending on the cause, we are going to develop new methods that is not known yet. For example, high fat accumulation in the cardiovascular diseases. They are the lipoproteins coming out from the liver. This is the drug that inhibits by affecting the liver due to this. Our drugs are blood vessel related drugs. So, even if we change how we approach it slightly, we might have a more creative and new drugs or treatment methods.

The value we strive for is a little different and a little more professional. Going deeper into it. This is the goal value we have.

Which of the KHIDI support program was helpful for you?

We made version1, and with the KHIDI startup package support business, we finished version2. We have applied for a patent. Now, we have IRB in Ajou University Hospital, and we are looking for people to participate in the clinical trial. When we recruit them, the clinical trial will be over before the second half of this year. With this, we are going to apply for medical device approval for version 2.

Last comments

We need version 3 to be fully automatic. And the business goal we are pursuing is to develop the cardiovascular treatment drugs and license out them after clinical approval. Already, several global pharmaceutical companies are reviewing our projects and they want to implement our system. This excites us.

The global news network AVING News has begun holding the MIK Hot Spot (Made in Korea Online Exhibition) to help small and medium-sized companies enter the market and attract investment 365 days a year. AVING News has been running online exhibitions since 2005 and had 975 online exhibitions so far. Its YouTube online exhibition has placed itself as Korea's largest online exhibition hall that opens with 19,000 videos (booths) with more than 800,000 visits per month which means more than 10 million visits per year.

The MIK HOT SPOT online exhibition is scheduled to be held regularly according to the field, target market, and participating institutions, and it will be presented as a new type of online business by transforming the know-hows and values of the participating companies according to the trend. Companies that want to participate can apply and apply through the marketing support projects from supporting institutions in the local governments. Refer to the institutions for more information.

→ Go to MIK Hot Spot (Made in Korea Online Exhibition) special page

→ Go to MIK Hot Spot (Made in Korea Online Exhibition) information page

Global News Network 'AVING'
by Jane Lee (www.aving.net)

Copyright ⓒ 2020 AVING. All Rights Reserved.   메일보내기 인쇄하기
  AVING Around the World  
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
 http://www.naver.com 
    latest Mobile/Computing
The World's First CIIE-themed Airplane Launched by CEA Flew t... 2020-07-13
At 5:36 on July 4, local time, the world's first CIIE-themed airplane flew from Shanghai to Paris Charles de Gaulle Inte
iQIYI Announces Major Upcoming Drama and Variety Show Release... 2020-07-13
iQIYI, Inc. (NASDAQ: IQ) ("iQIYI" or the "Company"), an innovative market-leading online entertainment service in China,
Five major Korean games premier at G4C Festival, ready to for... 2020-07-13
This month, you will have the opportunity to meet five major Korean games at the 17th annual Games for Change Festival (
The Toy Insider's Annual Summer Toy Party Goes Virtual with F... 2020-07-10
The Toy Insider, one of the toy industry's most influential organizations and a trusted go-to resource for parents and g
Customer Contact VIRTUAL: A Frost & Sullivan Executive MindXc... 2020-07-10
Due to the global health crisis and in the best interests of our participants, clients and employees, Frost & Sulliv
 
     
   
     

 
Copyright ⓒ 2020 AVING. All Rights Reserved.  Contact Webmaster for more Information